Targeting the autophagic network: A new frontier in colorectal cancer chemotherapy response

AUTOPHAGY AND THE CHEMORESISTANCE PHENOTYPE

The persistence of chemoresistance in CRC is increasingly understood not as a static genetic event but as a dynamic adaptive state in which autophagy plays a central regulatory role. Rather than a passive stress response, autophagy enables cancer cells to enter a reversible survival mode, maintaining metabolic homeostasis and preserving cellular integrity under cytotoxic assault.^[1,5]

Across therapeutic contexts, a consistent pattern emerges that treatments that disrupt nutrient or growth signaling, whether through epidermal growth factor receptor blockade, inhibition of DNA synthesis, or metabolic interference, tend to provoke compensatory autophagic activation.^[3,6] This phenomenon reflects a broader principle of metabolic plasticity, whereby tumor cells exploit autophagy to recycle essential components and sustain bioenergetic balance when anabolic pathways fail. By clearing damaged organelles and limiting the production of reactive oxygen species, autophagy effectively buys time for adaptation and survival.^[7]

Autophagy-driven resistance is not uniform but context-dependent. Its activation varies according to oncogenic background (e.g., KRAS or p53 status) and transcriptional regulators that define a tumor’s “autophagic tone.” The kruppel-like factor 4 and RAS related protein RAB-26 (KLF4-RAB26) axis, for example, redirects autophagy toward a drug-resistant phenotype^[4] while post-translational interference in tripartite motif-containing protein 21 mediated cellular myelocytomatosis oncogene degradation (TRIM21) stabilizes metabolic drivers and entrenches resistance.^[8] Chemoresistance thus emerges as an integrated systems property, shaped by the interplay of autophagic flux, metabolic signaling, and transcriptional control.

Therapeutically, the relationship between autophagy and chemoresistance is bidirectional. Inhibition can expose hidden metabolic vulnerabilities,^[6] whereas excessive activation can overwhelm adaptive capacity and precipitate autophagy-associated cell death.^[9-11] This duality reframes autophagy as a rheostat of cell fate, dictating whether a tumor adapts or succumbs to stress.

Viewing chemoresistance through the lens of autophagy reveals a crucial opportunity: autophagy does not simply accompany resistance but constructs it. Sustaining energy equilibrium and proteostasis under pharmacological pressure provides the architecture for adaptation.^[1,7] Therapeutic strategies that disrupt this equilibrium or push it beyond tolerance may transform a mechanism of endurance into one of vulnerability. Overcoming chemoresistance may depend less on new cytotoxins and more on controlling the timing and intensity of autophagic adaptation itself.^[5]

AUTOPHAGY-LINKED APOPTOSIS AND TUMOR SUPPRESSION

Long regarded as a survival mechanism, autophagy can, under certain conditions, become self-destructive, triggering apoptosis, and tumor suppression rather than protection.^[1,5] This redefinition challenges the traditional dichotomy of autophagy as either “good” or “bad,” suggesting instead that its outcome depends on how far the system is driven from homeostasis.

When autophagic flux surpasses a critical threshold, the so-called autophagic threshold, the process shifts from adaptation to collapse. Agents such as resveratrol and aripiprazole exemplify this transition, pushing cells beyond their adaptive limit and triggering autophagy-dependent apoptosis that restores chemosensitivity.^[9,11] The key distinction between cytoprotection and cytotoxicity lies not in the pathway itself but in its magnitude and persistence.

Autophagy and apoptosis are increasingly recognized as interconnected networks rather than competing processes. Excessive autophagy can degrade anti-apoptotic proteins, elevate reactive oxygen species, and destabilize mitochondria, converting a protective mechanism into a lethal one.^[10,12] Under oxidative or endoplasmic reticulum stress, as seen with artesunate exposure, autophagy initially restores balance but ultimately triggers senescence or apoptosis once compensatory capacity is exhausted.^[13] These dynamic reversals position autophagy as a metabolic checkpoint that decides between repair and destruction.

The tumor-suppressive consequences of autophagy also extend to immune regulation. Chaperone-mediated autophagy facilitates lysosomal degradation of immune checkpoint proteins such as B7-H3, enhancing immune recognition and limiting metastasis.^[14] Moreover, modulation of autophagic balance in T and NK cells influences their cytotoxic persistence.^[15] In this broader view, autophagy functions not only as an intrinsic death pathway but also as a bridge between metabolic stress and immune activation, redefining tumor suppression as a multicellular process.

Therapeutically, this understanding calls for a paradigm shift, from simply blocking autophagy to weaponizing it. Natural and repurposed compounds such as resveratrol, melatonin, andrographolide, and icaritin can convert a stress-buffering mechanism into a cell-killing one.^[10-12] Contemporary strategies thus aim to tune, rather than silence, autophagy, pushing tumor cells past their adaptive threshold while preserving normal-tissue resilience.^[16]

Collectively, these insights establish autophagy as a decision hub integrating metabolic signals, apoptotic machinery, and immune cues.^[17] The same machinery that sustains CRC cells under moderate stress can, when hyperactivated, dismantle them from within. Recognizing this duality transforms autophagy from a passive recycling route into a context-dependent determinant of fate, where therapeutic control of autophagic dynamics, not its simple inhibition, may reawaken its tumor-suppressive potential.^[1,5]

TRANSLATIONAL OUTLOOK AND PERSPECTIVES

The expanding evidence on autophagy in CRC reveals it as a biological fulcrum that can dictate therapeutic success or failure. What began as a cytoprotective mechanism has evolved into a framework explaining how cancer cells adapt, resist, or collapse under stress.^[1,5]

First, autophagy should be treated as a context-specific target, its modulation guided by the tumor’s genetic, metabolic, and transcriptional profile.^[3,4,8] Future progress depends on precision control of stress adaptation, tuning autophagic flux according to genotype and treatment stage.^[6,7]

Second, autophagy forms a vital bridge between metabolic control and immune regulation, influencing antigen presentation and checkpoint degradation.^[14,18] Integrating autophagy modulation with immunotherapy, particularly programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) regimens, offers new opportunities to transform resistant CRC into an immune-responsive disease.^[2,15]

Third, biomarker-driven and computational strategies will refine these approaches. Profiling autophagy-related markers (ATG5, LC3B, TRIM21, and KLF4) may enable patient stratification and rational therapy design, while modeling of autophagic flux and synthetic-lethal interactions can inform individualized interventions.^[7,19]

Ultimately, autophagy is emerging as a programmable therapeutic circuit. Integrating its modulation into chemo, targeted, and immunotherapies marks a step toward adaptive oncology, where treatments dynamically exploit cellular stress to overcome resistance.^[8,16] Once considered a silent accomplice of tumor endurance, autophagy may now become a strategic ally, a controllable mechanism that converts adaptation into vulnerability.

SUMMARY

Autophagy has emerged as a central regulator of chemotherapy response in CRC. Depending on the molecular and metabolic landscape, it can either sustain survival under cytotoxic stress or promote tumor cell death. Mechanistic studies implicating the ATF4 and DNA Damage-Inducible Transcript 4, KLF4-RAB26, TRIM21-c-Myc, and Sirtuin 1 and Forkhead Box Q1 axes reveal how autophagy integrates signaling networks to shape therapeutic outcomes.

Targeting the autophagic network, through inhibition of survival pathways or activation of lethal autophagy, offers a promising route to overcome drug resistance. The future of CRC therapy lies in context-specific precision modulation of autophagy, informed by biomarkers and integrated with multi-modal treatment strategies. As understanding deepens, autophagy may shift from a barrier to treatment success into a powerful therapeutic.